Rilotumumab
Rilotumumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against hepatocyte growth factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 2 | 2 | — | — | 5 |
| Carcinoma | D002277 | — | C80.0 | — | 3 | 1 | — | 1 | 4 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 3 | 1 | — | 1 | 4 |
| Adenocarcinoma | D000230 | — | — | 1 | 2 | 1 | — | — | 3 |
| Squamous cell carcinoma | D002294 | — | — | — | 1 | 1 | — | 1 | 2 |
| Squamous cell neoplasms | D018307 | — | — | — | 1 | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 3 | 3 | — | — | — | 4 |
| Glioma | D005910 | EFO_0000520 | — | — | 2 | — | — | — | 2 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Gliosarcoma | D018316 | — | — | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | 1 | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 1 | — | — | — | — | 1 |
| Acute disease | D000208 | — | — | 1 | — | — | — | — | 1 |
| Philadelphia chromosome | D010677 | — | — | 1 | — | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rilotumumab |
| INN | rilotumumab |
| Description | Rilotumumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743063 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 51WEW898IJ (ChemIDplus, GSRS) |
Target
Agency Approved
HGF
HGF
Organism
Homo sapiens
Gene name
HGF
Gene synonyms
HPTA
NCBI Gene ID
Protein name
hepatocyte growth factor
Protein synonyms
fibroblast-derived tumor cytotoxic factor, hepatocyte growth factor (hepapoietin A; scatter factor), Hepatopoietin-A, lung fibroblast-derived mitogen, Scatter factor, SF
Uniprot ID
Mouse ortholog
Hgf (15234)
hepatocyte growth factor (Q6LBE6)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 949 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
52 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use